Friday, 16 October 2026European Markets

REXEL And NEURONES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - rexel (rxl.pa) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
rexel (rxl.pa) €21.29 3.87% 18.74%
neurones (nro.pa) €40.85 2.75% 14.2%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. rexel (rxl.pa)

3.87% forward dividend yield and 18.74% return on equity

rexel s.a., together with its subsidiaries, engages in distribution of low and ultra-low voltage electrical products and services for the residential, commercial, and industrial energy markets in france, europe, north america, and asia-pacific. the company offers smart cameras, sensors, controllers, and monitoring software; light sources, lights, and control switches; climate control products, including heat pumps, air conditioning, and water heaters; fire alarms, surveillance equipment, access controls devices, and emergency lightings; and connection cables, and switches and routers, as well as enclosures, mounts, and racks. it also provides solar modules and inverters; connected lighting, intelligent home system, home control touch screen, and smart thermostat products; residential chargers, commercial stations, and charging cables for electric vehicles; electric motors, variable speed drives, programmable logic controllers, and computers and operator interface; and fastening systems, electrical power and control, and valves and instrumentation products. the company offers products, services, and solutions in the fields of technical supply, automation, and energy management related to the construction, renovation, maintenance, and production. it operates a network of approximately 1,900 branches in 21 countries. the company was founded in 1967 and is headquartered in paris, france.

earnings per share

as for profitability, rexel has a trailing twelve months eps of €3.14.

pe ratio

rexel has a trailing twelve months price to earnings ratio of 6.78. meaning, the purchaser of the share is investing €6.78 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.74%.

revenue growth

year-on-year quarterly revenue growth grew by 26%, now sitting on 18.7b for the twelve trailing months.

volume

today's last reported volume for rexel is 253883 which is 73.28% below its average volume of 950277.

moving average

rexel's value is above its 50-day moving average of €20.34 and way higher than its 200-day moving average of €19.32.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, rexel's stock is considered to be oversold (<=20).

more news about rexel.

2. neurones (nro.pa)

2.75% forward dividend yield and 14.2% return on equity

neurones s.a., an information technology (it) services company, provides infrastructure, application, and consulting services in france and internationally. its infrastructure services include infrastructure management, clouds, user support, devops, cybersecurity, it service management, information system governance, and automation. the company also provides application services in the areas of sap integration and outsourcing; mobility, data, iot, digital, agile, ux/ui, and devops; it consulting for finance, big data, ai and blockchain; content management, business process management, paperless process; and it training and working with change management. in addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, devops, ci/cd, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, ux/ui, and digital marketing, as well as internal process digitization, ecm/bpm, rpa, dematerialization, ai, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. the company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. neurones s.a. was founded in 1984 and is headquartered in nanterre, france.

earnings per share

as for profitability, neurones has a trailing twelve months eps of €1.82.

pe ratio

neurones has a trailing twelve months price to earnings ratio of 22.45. meaning, the purchaser of the share is investing €22.45 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.2%.

moving average

neurones's value is higher than its 50-day moving average of €38.50 and above its 200-day moving average of €37.65.

revenue growth

year-on-year quarterly revenue growth grew by 16.4%, now sitting on 665.38m for the twelve trailing months.

more news about neurones.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com